Research article

β-Glucuronidase inhibitory activity of bromophenol isolated from red alga

Grateloupia lancifolia

The Han Nguyen1,*, Patrick Achiever Blamo Jr1, Xiaoyong Liu2, Thi Van Anh Tran3 and Sang Moo Kim4,*

1 Faculty of Food Technology, Nha Trang University, 02 Nguyen Dinh Chieu Street, Nha Trang City, Khanh Hoa, Vietnam
2 Haizhibao Deutschland GmbH, Heiliggeistgasse 28, 85354 Freising Munish, Germany
3 Faculty of Pharmacy, University of Medicine and Pharmac at Ho Chi Minh City, 41 Dinh Tien Hoang Street, Ho Chi Minh City, Vietnam
4 Department of Marine Food Science and Technology, Gangneung-Wonju National University, 7 Jukheon-gil, Gangneung 25457, Republic of Korea

* Correspondence: Email: hannt@ntu.edu.vn; smkim@gwnu.ac.kr.

Abstract: The human gastrointestinal (GI) tract plays an important role in disease and health. The overexpression of β-glucuronidase, an enzyme produced in the gastrointestinal tract, has been found to cause the retoxification of potentially damaging substances already detoxified by liver glucuronidation. Thus, β-glucuronidase has been implicated in a number of diseases including colon cancer, liver disease and Crohn’s disease. This study investigated β-glucuronidase inhibitory activity of a bromophenol purified from the red alga Grateloupia lancifolia. Using an assay-guided fractionation technique, a bromophenol, bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, a bromophenol, was isolated from the red alga G. lancifolia. Its structure was elucidated on the basis of extensive 1D- and 2D-NMR studies, high resolution EI-MS analysis and comparisons with literature data. Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether showed potent β-glucuronidase inhibitory activity. The IC50 and Ki values of bromophenol against E. coli β-glucuronidase were 0.54 and 0.53 mM, respectively. This bromophenol inhibited β-glucuronidase competitively and was stable at pH 2 up to 40 min at 37 °C.

Keywords: β-glucuronidase inhibitor; bromophenol; Grateloupia lancifolia
1. Introduction

The human gastrointestinal (GI) tract plays an important role in disease and health [1]. The GI tract has a dense microbial system that includes both aerobic and anaerobic microorganisms [2]. A study by Li et al. [3] suggested that gut microbiota composition is shaped by environmental factors, such as diet, and possibly also by host genetics. The gut microbiota provides benefits to the host by improving energy recovery from undigested food, defending the body against pathogens and interacting with both the immune and nervous systems to human metabolism by providing enzymes that are not encoded by the human genome [4]. Some of these enzymes include β-glucuronidase, β-glucosidase, β-galactosidase, nitroreductase, azoreductase, 7-α-dehydroxylase, and cholesterol dehydrogenase [5].

β-Glucuronidase (E.C.3.2.1.31) is widely distributed in plants, animals and bacteria. It is produced by some gastrointestinal bacteria, including Clostridia, Bacteroidacea, Eubacteria, Peptostreptococci and Bifidobacteria [5]. It hydrolyses glucuronidated compounds, liberating glucuronic acid and the aglycone form that can be an imine, a thiol or an alcohol [6]. However, an increased activity of this enzyme is capable of retoxifying compounds that have been detoxified by liver glucuronidation, which is one of the most important detoxication processes in the liver [5]. It hydrolyzes glucuronide to liberate xenobiotics which exhibit toxicity in the intestine and decrease the excretion rate of xenobiotic via reabsorption [7]. The excessive expression of the enzyme has been implicated in a number of diseases including colon cancer [8], Crohn’s disease [6], liver cancer and liver damage [9]. Bacterial β-glucuronidase inhibitors will promote excretion of xenobiotics and thus reducing the carcinogenic potential of toxic compounds [10]. Thus, finding novel β-glucuronidase inhibitors, especially from natural resources, would be of considerable importance.

Seaweeds are rich in pigment and polysaccharides, and have been known to possess antioxidative properties [11], antimicrobial activity [12] and anticancer activity [13]. A few reports are available for carbohydrate inhibitory activities, in which most researches focused on α-glucosidase [14], β-D-glucanase [15], and aldose reductase inhibitors [16]. Sekikawa et al. [7] reported that the methanol extracts of Chondria crassicaulis inhibited β-glucuronidase but could not identify the inhibitory compound. They found that the inhibitory components differed from each other due to the different inhibition mechanisms. In our previous study [5], β-glucuronidase inhibitors purified from Grateloupia elliptica were characterized.

The edible red alga G. lancifolia belonging to Halymeniaceae family, has been reported on antioxidant, tyrosinase and cholinesterase inhibitory activities in the previous study [17]. A bromophenol, bis (2,3-dibromo-4,5-dihydroxybenzyl) ether, was purified from G. lancifolia collected in the eastern coastal area of Korean peninsula. The isolated compound has been investigated for its α-glucosidase inhibitory activity in our previous study [18]. In the present study, the stability, kinetics and inhibitory activity of bis(2,3-dibromo-4,5-dihydroxybenzyl) ether isolated from G. lancifolia against β-glucuronidase were investigated.

2. Materials and methods

2.1. Reagents

β-Glucuronidase and p-nitrophenyl-β-D-glucuronide (pNPG) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Sephadex LH-20 was purchased from Pharmacia Biotech Ltd. (Uppsala, Sweden). The other chemicals used in this study were of analytical grade.

2.2. Algal sample

*G. lancifolia* was harvested in the eastern coastal area of Korean peninsula in July and August 2017. For identification, the seaweed was fixed with 10% formalin-seawater (v/v) immediately after collected and transported to laboratory, then the sample was identified by microscope according to the method of De Clerck et al. [19]. Fresh alga was washed with tap water and air-dried in the shade at room temperature. Dried sample was cut into small pieces (2 × 3 cm), homogenized, sifted with a 500 μm sieve, and then stored at −40 °C until use.

2.3. Extraction and purification of β-glucuronidase inhibitor

β-Glucuronidase inhibitor was purified according to the method of Kim et al. [18]. The structures of β-glucuronidase inhibitor were identified by spectroscopic methods including ¹H-NMR, ¹³C-NMR, and EI-MS. ¹H and ¹³C-NMR spectra were recorded in methanol-d₄ (MeOD) on a Bruker DRX-600 spectrometer (Bruker, Karlsruhe, Germany). Mass spectra were recorded on JEOL JMS-AX500 and JEOL JMS-SX102A spectrometers (Jeol, Tokyo, Japan).

2.4. Inhibitory assay of β-glucuronidase activity

β-Glucuronidase inhibitory activity was determined according to the method of Kim et al. [5]. 0.01 mL of 10 mM pNPG in 0.01 M phosphate buffer (pH 7) was premixed with 2.2 mL of sample solution and 0.01 mL of 20 U β-glucuronidase in the same buffer was added to the mixture to start the reaction. The reaction was carried out at 37 °C for 60 min and stopped by adding 1.5 mL of 0.1 M Na₂CO₃. Enzymatic activity was quantified by measuring the absorbance at 405 nm. One unit of β-glucuronidase activity was defined as the amount of enzyme liberating 1.0 μM of p-nitrophenol per min. One unit of β-glucuronidase inhibitory activity was defined as one unit decrease of β-glucuronidase activity. The IC₅₀ value is defined as the inhibitor concentration to inhibit 50% of its activity under assayed conditions.

2.5. Stability of β-glucuronidase inhibitor

The stability of bromophenol at pH 2 and 37 °C was performed according to the method of Kim et al. [18]. Bromophenol was dissolved in a small amount of methanol and adjusted to a pH 2 with HCl, and then stood up at 37 °C for 0, 20, 40, and 60 min. The inhibitory activity of bromophenol against *E. coli* β-glucuronidase was determined as the mentioned above. The relative inhibitory activity of bromophenol at pH 2 was calculated based on the inhibitory activity of the control at pH 7.

2.6. Kinetics of β-glucuronidase inhibitor

The enzyme-inhibitor reaction was performed according to the mentioned above at 0.15 and 0.3 mM of inhibitor. The type of inhibition was determined using the Lineweaver-Burk plot [20], double
reciprocal plot, of the substrate concentration and velocity. The inhibition constant ($K_i$ value) was determined by Dixon plot analysis.

2.7. Statistical analysis

Statistical analysis of the data was carried out by Duncan’s multiple comparison test ($p < 0.05$) using the SPSS software package version 11.0 program from SPSS Inc. (Chicago, IL, USA).

3. Results and discussion

3.1. Extraction and purification of $\beta$-glucuronidase inhibitor

The inhibitory activity of aqueous MeOH extract of $G$. lancifolia against $\beta$-glucuronidase was 28.4% at 5 mg mL$^{-1}$ [5], 80% MeOH was the best extractive solvent in terms of $\beta$-glucuronidase inhibitory activity, followed by 80% Me$_2$CO and 100% MeOH in order (data not shown). Therefore, 80% MeOH was used to extract $\beta$-glucuronidase inhibitor from $G$. lancifolia in the present study. The MeOH extraction was concentrated in vacuum and successively partitioned with $n$-hexane, CHCl$_3$, EtOAc and $n$-BuOH. In the consecutive solvent fractionations of inhibitors, $\beta$-glucuronidase inhibitory activities of the EtOAc fraction at concentrations of 0.1, 1, and 4 mg mL$^{-1}$ were 22.3%, 42.4%, and 55.4%, respectively, whereas those of BuOH fraction were 13.4%, 13.4%, and 15.5% (Table 1). However, no $\beta$-glucuronidase inhibitory activities were observed in the $n$-hexane, CHCl$_3$ and water fractions. Lipids, chlorophyll, refined oil and sterol are dissolved and fractionated in $n$-hexane, and resin is usually extracted with CHCl$_3$. In addition, polyphenols such as flavonoid and tannin are extracted in EtOAc, and water-soluble components are shifted over in BuOH [21]. The present study found that a large amount of solute in 80% MeOH extract was shifted over to $n$-hexane (62.2%) and CHCl$_3$ (12.1%), but neither had any $\beta$-glucuronidase inhibitory activity at up to 4 mg mL$^{-1}$ (Table 1). The results suggested that phenolic compounds could be responsible for $\beta$-glucuronidase activity of $G$. lancifolia.

<table>
<thead>
<tr>
<th>Solvent fractions</th>
<th>Yield (%)</th>
<th>$\beta$-Glucuronidase inhibitory activity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0.1 mg mL$^{-1}$</td>
</tr>
<tr>
<td>$n$-Hexane</td>
<td>65.2 ± 3.2</td>
<td>NI</td>
</tr>
<tr>
<td>Chloroform</td>
<td>12.1 ± 0.9</td>
<td>NI</td>
</tr>
<tr>
<td>Ethyl acetate</td>
<td>12.3 ± 0.8</td>
<td>22.3 ± 1.4</td>
</tr>
<tr>
<td>$n$-Butanol</td>
<td>5.4 ± 0.5</td>
<td>13.4 ± 0.8</td>
</tr>
<tr>
<td>Water</td>
<td>6.3 ± 0.6</td>
<td>NI</td>
</tr>
</tbody>
</table>

NI: No inhibition.

The active compound was purified according to our published procedures [18]. The structure of $\beta$-glucuronidase inhibitor from $G$. lancifolia was identified as bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, a bromophenol (Figure 1), according to spectral data [18]. The structure of $\beta$-glucuronidase inhibitor, bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, purified from $G$. lancifolia was different from
2,4,6-tribromophenol and 2,4-dibromophenol purified from *G. elliptica* (Halymeniaceae) in the previous study [5] but was the same as bromophenol from *G. lancifolia* [18] and *Rhodomela confervoides* [22]. β-Glucuronidase inhibitors are categorized as terpenoids and their glucuronides, flavonoids and their glucuronides, and pseudo-sugar containing nitrogen [23], in which bromophenols are classified into phenolic compounds.

Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether. Ei-MS (positive) *m/z* 581 (17), 579 (67), 577 [M]+ (100), 575 (71), 573 (19), ¹H NMR (600 MHz, MeOD) δH 7.14 (2H, s, H-6, 6’), 4.59 (4H, s, H-7, 7’), ¹³C NMR (150 MHz, MeOD) δC 131.3 (C-1, 1’), 114.7 (C-2, 2’), 113.8 (C-3, 3’), 144.7 (C-4, 4’), 145.6 (C-5, 5’), 115.6 (C-6, 6’), 73.2 (C-7, 7’).

![Bromophenol](image)

**Figure 1.** Bromophenol purified from *Grateloupia lancifolia*.

3.2. **Inhibitory activity of bromophenol against β-glucuronidase**

IC₅₀ and *K*ᵢ (inhibition constant) values of the *G. lancifolia* bromophenol against *E. coli* β-glucuronidase were 0.54 and 0.53 mM, respectively (Table 2), which is much more effective than 2,4,6-tribromophenol (5.4 mM of IC₅₀) and 2,4-dibromophenol (8.5 mM of IC₅₀) purified from *G. elliptica* [5]. The *G. lancifolia* bromophenol inhibited β-glucuronidase competitively (Figure 2, Table 2).

![Lineweaver-Burk plot](image)

**Figure 2.** Lineweaver-Burk plots of *E. coli* β-glucuronidase inhibition of bromophenol purified from *Grateloupia lancifolia* at different concentrations of pNPG.
Table 2. IC₅₀ value, inhibition constant and mode of bromophenol purified from Grateloupia lancifolia.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ (mM)</th>
<th>Kᵢ (mM)</th>
<th>Inhibition mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bromophenol</td>
<td>0.54 ± 0.03</td>
<td>0.53 ± 0.02</td>
<td>Competitive</td>
</tr>
</tbody>
</table>

Polyphenolic compounds from terrestrial plants are typically derived from gallic and ellagic acid, while phenolics from marine macroalgae range from basic molecules such as phenolic acids to highly complex phlorotannin (PHT) compounds [24] thus might result in exerting inhibitory activity. For example, o-quinones derived from catechols are covalently bound to protein amino acid and thiol groups [25]. Algal β-glucuronidase inhibitor, bromophenol, belongs to phenolic compounds could bind to both active and non-active site of the enzymes [26,27]. These results suggested that bromophenol of red alga, *G. lancifolia* is an effective inhibitor against β-glucuronidase.

Endo-β-D-glucuronidase (commonly referred to as heparanase) is an extracellular matrix enzyme that degrades heparin sulfate and heparin sulfate proteoglycans, the major components of extracellular matrix and basement membrane [28]. Therefore, this enzyme is thought to accelerate cancer invasion and metastasis, and is expressed to a higher extent during inflammation, angiogenesis or malignant transformation [29]. Oral administration of *Lentinus edodes* significantly inhibited mouse fecal β-glucuronidase and tryptophanase [30]. Gudiel-Urbano and Goni [31] also reported that the intestinal β-glucuronidase activity in rats decreased when seaweeds (*Undaria pinnatifida* and *Porphyra ternera*) were fed. Crude drug containing β-glucuronidase inhibitor decreased toxic side effects of the metabolite SN-38 of the anticancer agent CPT-11 [32]. Guo et al. [33] mentioned that soybean saponins were effective in inhibiting colon cancer in rats by downregulating the activity of β-glucuronidase in colonic mucosa but not the COX-2 protein expression and PGE2 level. Hence, bromophenol purified from *G. lancifolia*, a potent β-glucuronidase inhibitor, can be used as a novel pharmaceutical agent for the prevention and treatment of colon cancer.

### 3.3. Stability of bromophenol against β-glucuronidase

The acidic condition (pH 2) was used to mimic the pH encountered by bromophenol in the stomach. The inhibitory activity of bromophenol against *E. coli* β-glucuronidase was very stable at pH 2 and remained approximately 96, 94 and 78% for 20, 40 and 60 min, respectively (Figure 3). This result suggested that the bromophenol purified from *G. lancifolia* was very stable under acidic condition and can be a candidate for development of a β-glucuronidase inhibitor.
Figure 3. Stability of bromophenol purified from Grateloupia lancifolia against \( \beta \)-glucuronidase at pH 2.

4. Conclusions

In this study, bis(2,3-dibromo-4,5-dihydroxybenzyl) ether with a strong \( \beta \)-glucuronidase inhibitory effect was purified from macroalga G. lancifolia. The isolated compound showed the good effect on \( \beta \)-glucuronidase and was very stable in acidic condition. It is suggested that this bromophenol could be developed as a novel natural pharmaceutical agent. However, the result was just obtained in vitro, therefore further study should be carried out in vivo for commercial application.

Acknowledgements

This study was in part financially supported by the Project of Khanh Hoa Province (No. DT-2017-20902-DL to Dr. The Han Nguyen), Vietnam.

Conflict of interest

The authors declare no conflict of interest.

References


© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)